Fluoroquinolone-Associated Disability (FQAD) Cases in Patients Being Treated for Uncomplicated Sinusitis, Bronchitis, and/or Urinary Tract Infection
|
|
|
- Eric Manning
- 6 years ago
- Views:
Transcription
1 Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 5, 2015 FDA s Adverse Event Reporting System (FAERS) Review: Fluoroquinolone-Associated Disability (FQAD) Cases in Patients Being Treated for Uncomplicated Sinusitis, Bronchitis, and/or Urinary Tract Infection Debra Boxwell, PharmD Division of Pharmacovigilance II Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration 1
2 2013 Pharmacovigilance Review: Disabling Peripheral Neuropathy Associated with Systemic Fluoroquinolone Exposure 2013 FDA review describing disabling peripheral neuropathy associated with fluoroquinolone use. This resulted in a labeling change describing the potential for irreversible peripheral neuropathy. 76% of patients with peripheral neuropathy also reported adverse events (AEs) involving other organ systems, including neuropsychiatric, musculoskeletal, vision, and cardiac events. The duration of many of these other adverse events also appeared to be prolonged and disabling. 2
3 Fluoroquinolone-Associated Disability (FQAD) This review was done to try to characterize the constellation of disabling symptoms that was seen in the previous review, which we will refer to as fluoroquinolone-associated disability, or FQAD. Disability: A substantial disruption of a person's ability to conduct normal life functions. (CFR - Code of Federal Regulations Title 21, Sec : Postmarketing reporting of adverse drug experiences) Must have adverse events reported from two or more of the following body systems: Musculoskeletal Neuropsychiatric Peripheral Nervous System Senses (vision, hearing, etc.) Skin Cardiovascular AEs had to last 30 days or longer after stopping the fluoroquinolone. 3
4 Few articles in peer-reviewed literature that describe this constellation of disabling symptoms Jay S. Cohen, MD (Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001;35: ) Collected additional information on severe, long-term adverse events that affected other organ systems Beatrice A. Golomb, MD (Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisystem adverse effects. BMJ Case Rep 2015 Oct 5. pii: bcr doi: /bcr ) UCSD Fluoroquinolone Effects Study Currently enrolling patients online 4
5 Reports consistent with FQAD were more likely to be found in the lay press Newspapers: New York Times (9/10/12), USA Today (9/17/14), Washington Post (8/3/15) TV news reports Websites Social media 5
6 Benefits FAERS Benefits and Limitations FAERS is a spontaneous (voluntary) reporting system Clinical trials are usually done in hundreds of people; once a product goes to market, it is often used by millions of people FAERS has the ability to detect rare and serious adverse events 6
7 Limitations FAERS Benefits and Limitations There is underreporting Causality may be difficult to determine Reports must be reviewed and evaluated for: Concomitant drugs Medical history and co-morbid conditions Temporal relationship of drug administration to the event Not all reports contain enough detail to properly evaluate an event 7
8 FQAD Population Goal: To identify FQAD cases reported to FAERS in a very specific population: Reported to be previously healthy before taking an oral FQ antibiotic Treated for uncomplicated sinusitis, bronchitis, and UTI A healthy patient was a person able to perform all of the usual activities of daily living without significant restrictions prior to taking the FQ Patients were included if they had controlled chronic diseases, such as hypertension, hypothyroidism, or hyperlipidemia 8
9 Search Criteria Reports were searched in FAERS with the following criteria: Oral dosage forms for the 5 available fluoroquinolones US cases Outcome reported as disability Indications of uncomplicated sinusitis, bronchitis, and/or cystitis/uti* Search from November 1, 1997 to May 30, 2015 All MedDRA Preferred Terms (PT) (or adverse event terms) were searched *Indications PT: Sinusitis acute, Sinusitis bacterial, Sinusitis, Bronchitis acute, Bronchitis, Bronchitis bacterial, Cystitis, Acute cystitis, Cystitis bacterial, Urinary tract infection, UTI-urinary tract infection, Urinary tract infection bacterial 9
10 Disability Search Results Fluoroquinolone Number of Reports Levofloxacin 592 Ciprofloxacin 358 Moxifloxacin 136 Ofloxacin 32 Gemifloxacin 4 TOTAL 1,122 May include duplicate reports. 10
11 Percentage of Disability Reports* Among all Serious Outcome Reports with Selected Antibiotics for Treatment of Uncomplicated Sinusitis, Bronchitis, and UTI Ofloxacin (32/103) Ciprofloxacin (358/1221) Levofloxacin (592/2201) 26.9% 29.3% 31.1% Gemifloxacin (4/38) Moxifloxacin (136/1371) 10.5% 9.9% Cefdinir (2/29) Nitrofurantoin (34/504) Amoxicillin (6/100) Doxycycline (4/67) Amox/Clav (13/254) Clarithromycin (24/516) Cotrimoxazole (34/817) Cephalexin (2/73) Azithromycin (12/1176) 6.9% 6.7% 6.0% 6.0% 5.1% 4.6% 4.2% 2.7% 1.2% Green=fluoroquinolone Blue=other antibacterial agent 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% *Number of US reports reporting disability divided by the total number of US serious adverse event reports for oral dosage forms, from November 1, 1997 to May 30,
12 FQAD Cases After retrieving the 1,122 reports, individual review of each report was needed to further identify cases of FQAD: To identify that the patient had adverse events reported from two or more of the following body systems: Musculoskeletal Neuropsychiatric Peripheral Nervous System Senses (vision, hearing, etc.) Skin Cardiovascular That the AEs lasted 30 days or longer after stopping the fluoroquinolone 12
13 Exclusions Reports meeting FAERS search criteria (n=1,122) Excluded Reports (n=944) Reported a disabling AE, but from less than two of the selected body systems: n= 540 (57%) FQAD Case Series (n=178) Events lasted for less than 30 days after stopping the FQ: n=139 (15%) Complicated or confounded drugs or medical history: n= 102 (11%) Diagnosed with an indication other than uncomplicated sinusitis, bronchitis, or UTI: n= 101 (11%) Duplicate report: n= 33 (3%) Case found in another FQ report: n=17 (2%) Not enough information to clinically evaluate: n=12 (1%) 13
14 US Disability Reports Associated with Oral Fluoroquinolones and FQAD Cases Total Disability Reports* Total FQAD Cases Percentage of Cases Levofloxacin % Ciprofloxacin % Moxifloxacin % Ofloxacin Gemifloxacin TOTAL 1,122 reports 178 cases *Reports: All individual reports coming into FAERS, including duplicate reports Cases: Reports have been de-duplicated, assessed for clinical relevance, did not meet the exclusion criteria 14
15 FAERS Search Results Descriptive Characteristics of FQAD Cases Reported to FDA from November 1, 1997 May 30, 2015 (N=178) Age (n=173) Mean: 48.1 years Median: 48 years Range: years Sex Female: 138 (78%) Male: 40 (22%) 0-29 years: n=15 (9%) years: n=128 (74%) 60 years: n=30 (17%) < 18 years: n=2 (1%) After removing all UTI cases (n=93): Female: 74%; Male: 26% Reported Indication for FQ Therapy Cystitis/UTI 84 (47%) Sinusitis 59 (33%) Bronchitis 26 (15%) Sinusitis/bronchitis 7 (4%) Bronchitis/UTI 1 (<1%) Sinusitis/bronchitis/UTI 1 (<1%) Report type Direct: 152 (85%) Expedited: 18 (10%) Non-expedited: 8 (5%) 15
16 FAERS Search Results Descriptive Characteristics of FQAD Cases Reported to FDA from November 1, 1997 May 30, 2015 (N=178) Onset of AEs from start of FQ therapy (n=102) Mean: 5.4 days Median: 3 days Range: 1 hour 3 months Onset 1 2 days of starting FQ: n=49 (48%) Onset 3-4 days of starting FQ: n=20 (20%) Onset 5-10 days of starting FQ: n=21 (20%) Onset >10 days of starting FQ: n=12 (12%) Duration of AEs at the time the report was received by the FDA (n=166) Mean: 61.2 weeks (14 months) Median: 30 weeks (7 months) Range: 30 days 9 years 1 year: n=39 (23%) 16
17 Body Systems in FQAD Cases (n=178) Organ Systems Percentage of Cases Involved Musculoskeletal (tendon/joint/muscle) 97% Neuropsychiatric 68% Peripheral Nervous System 63% Senses (vision, hearing, etc.) 32% Skin 15% Cardiovascular 12% 17
18 Reported Musculoskeletal Events* [tendon/joint/muscle] (n=173) Joint pain (113) Tendon pain/tendonitis (66) Muscle pain (52) Muscle weakness (39) Joint swelling (20) Muscle cramps or spasms (17) Tendon rupture (14) Joint popping or cracking (13) Limb pain and swelling (11) Joint stiffness (11) Unlabeled events are underlined *Patients may have reported more than 1 event in each body system 18
19 Reported Neuropsychiatric Events* (n=121) Fatigue (43) Insomnia (38) Anxiety (33) Headaches (24) Dizziness (23) Depression (19) Brain fog (18) Nightmares (15) Memory impairment (12) Confusion (10) Lightheadedness (9) Panic attacks (8) Impaired concentration (8) Loss of balance (8) Vertigo (8) Hallucinations (6) Disorientation (5) Feeling like something crawling on/under skin (4) Malaise (4) Unlabeled events are underlined *Patients may have reported more than 1 event in each body system; only AEs with 4 reports were displayed 19
20 Reported Peripheral Nervous System Events* (n=113) Peripheral neuropathy (50) Numbness (41) Tingling (35) Burning pain (36) Electrical or shooting pain (19) Twitching (17) Tremors (15) Pins & needles sensation (5) Paresthesias (3) Prickling (1) Unlabeled events are underlined *Patients may have reported more than 1 event in each body system 20
21 Reported Senses Events* (n=57) Eye pain (16) Diminished vision (15) Tinnitus (14) Blurred vision (11) Hearing impairment (5) Pressure in ears (2) Loss or altered taste (2) Sensitivity to light (1) Double vision (1) Retinal tear (1) Ear pain (1) Loss of smell (1) Unlabeled events are underlined *Patients may have reported more than 1 event in each body system 21
22 Reported Cardiovascular Events* (n=22) Palpitations (16) Tachycardia (10) Chest pain/discomfort (4) Reported Skin Events* (n=27) Ongoing skin rash or acne (13) Sweating (7) Photosensitivity (7) Skin sensitivity to touch (6) Hair loss (5) Flushing (4) Unlabeled events are underlined *Patients may have reported more than 1 event in each body system 22
23 Venn Diagram of FQAD Cases that Reported an Adverse Event in the Top 3 Body Systems (n=178) Peripheral Nervous System n=113 (63%) n=73 (41%) n=67 (38%) n=107 (60%) n=120 (67%) Neuropsychiatric n=121 (68%) Musculoskeletal n=173 (97%) 23
24 Percentage of FQAD Cases for Each Fluoroquinolone by Body System Levofloxacin (n=91) Ciprofloxacin (n=65) Moxifloxacin (n=19) Ofloxacin (n=2) Gemifloxacin (n=1) Peripheral nervous system Senses Musculoskeletal Neuropsychiatric Cardiovascular Skin 98% 52% 74% 30% 10% 10% 94% 78% 66% 31% 12% 15% 95% 79% 65% 30% 10% 15%
25 Case Report 25
26 Case report: 49-year-old woman, 2004 This patient received a 10-day supply of levofloxacin 500 mg to treat a sinus infection. The symptoms began 2 days after starting the drug. Prior to taking this drug, I was a healthy 49-year-old, an advanced downhill skier, with NO medical problems. I could barely walk, had to crawl up my staircase. I had severe muscle weakness, muscle burning and joint pain in all my limbs I ached and burned in what seemed every tendon and muscle in my body I continue to suffer 22 months later with the following disabling conditions: Severe tendon/muscle pain and tightness, tendonitis, tingling, numbness, prickling, pins and needles sensations in my extremities. Electrical sensations. Feeling of worms crawling under my skin. Severe arm and leg weakness. Muscle twitching, spasms and contractions. Severe muscle tenderness. To poke my muscles feels like a bee sting! Inability to sleep due to pain 24 hours per day, 7 days per week. Inability to work due to pain and weakness. Difficulty thinking clearly, confusion. Chronic fatigue. 26
27 Observations No one fluoroquinolone appeared to have a greater association with FQAD than another. Direct reports: 85% is an unusually high number Over past 10 years, the percentage of direct reports for all drugs has ranged from approximately 2-6%. The unusually large number of direct reports coming from patients who described similar experiences after taking a FQ was very beneficial in describing these disability cases. 27
28 Observations The current Box Warning states that tendonitis and tendon rupture can occur in all ages, but that there is an increased risk in older patients, usually over 60 years of age. In this case series, only 17% of all patients were found to be 60 years of age or older. In addition, the percentage of tendonitis/tendon rupture cases were the same in both the younger and older age groups. Majority (74%) of cases were reported in patients years old. 28
29 Observations Many of the patient s clinicians were reported to be at a loss as to what was causing these symptoms. Some patients reported extensive medical testing to try to diagnose the cause of their disability symptoms, but test results were frequently negative. Effective treatments were not identified. 29
30 Observations Most of the individual AEs that exist within FQAD are currently described in fluoroquinolone labels. However, the constellation of disabling symptoms described here is not in the label. The decrease in quality of life was described as being profound, and it affected both the patient and his/her family. 30
31 Thank you for your attention MedWatch website-- 31
Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart
Name Diagnosis Date Pathogens Present Date GENERAL Fever Chills Night sweats Fatigue Poor Stamina Weight Loss/Gain Gernalised Pain Migratory Pain Shooting Pain Daytime Napping Menstrual Irregularity Milk
Headache Follow-up Visit Form
!1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:
PATIENT INFORMATION LEAFLET CARZIN XL
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it
N N X X === === === === N N X X === u u s s. Physician Signature: OrthoNeuro
Physician Signature: OrthoNeuro Date: Name: Date: Age: SS#: Sex: DOB: Referring Physician: Referring Physician Address: Mark the areas on the corresponding figures where you feel the described sensations.
Patient Name: Date of Birth: Patient Name: DOB: Patient Guardian/Representative: How old are you. Handed: Right Left Ambidextrous Male
Patient Name: Welcome to Cerebrum Health Centers. Carefully complete all of the following health history questionnaires. The accuracy of your answers will help us better diagnose and treat your condition.
INITIAL PATIENT FORM
Patient : INITIAL PATIENT FORM Reason for your visit: Visit Date: Left CIRCLE AREA(S) OF CONCERN: Right TOP/BOTTOM OUTSIDE INSIDE Type of pain: Sharp Burning Soreness Tightness Stabbing Numbness Aching
SECTION OF NEUROSURGERY PATIENT INFORMATION SHEET
SECTION OF NEUROSURGERY PATIENT INFORMATION SHEET EC#: (for office use only) Patient s Name: Today s Date: Age: Date of Birth: Height: Weight: Physician you are seeing today: Marital Status: Married Work
What do you believe is causing your most important health concern?
Intake form Name Today s Date Date of Birth Address City Phone Postal Code Email Primary Health Care Provider Emergency Contact Phone Note: By providing your email address you are giving us consent to
Name: Date: Street Address: Referring Physician: How long have you had your current problem?
3851 Piper Street, Suite U464 Anchorage, AK 99508 p 907.339.4800 f 907.339.4801 New Patient Health Questionnaire Name: Date: Street Address: City: State Zip Sex: Age: Birth Date: Insurance: SS# Home Phone:
ARE SALINE IMPLANTS REALLY SAFE?
ARE SALINE IMPLANTS REALLY SAFE? By Dr. Michael John Badanek, BS, DC, CNS, CTTP, DACBN, DCBCN, MSGR./CHEV The Saline Controversy The moratorium enacted by the FDA in 1992 did not explicitly forbid silicone
New Patient Pain Evaluation
New Patient Pain Evaluation Name: Date: Using the following symbols, mark the areas of the body diagrams which are affected by your pain: \\ = Stabbing * = Electrical X = Aching N = Numbness 0 = Dull S
NEW PATIENT REGISTRATION PLEASE COMPLETE ALL ITEMS ON EACH PAGE. Name (Last, First, M.I.) Address. City State Zip Code. Phone ( ) Work ( ) Cell ( )
NEW PATIENT REGISTRATION PLEASE COMPLETE ALL ITEMS ON EACH PAGE Date Name (Last, First, M.I.) Address City State Zip Code Phone ( ) Work ( ) Cell ( ) Date of Birth Age Marital Status SSN Employer Employer
N N X X === === === === N N X X === u u s s. Physician Signature: OrthoNeuro
Physician Signature: OrthoNeuro Date: Name: Date: Age: SS#: Sex: DOB: Referring Physician: Referring Physician Address: Mark the areas on the corresponding figures where you feel the described sensations.
Lyme Disease Specific Symptoms
Did you have: Please indicate yes or no (Y / N) and/or date month/year tick bite spotted rash over large area circular or bull-eye rash linear red streaks Lyme test date(s) mm/year Results: (positive +,
New Patient Medical History and Intake Form Medical Marijuana ( MMJ ) Certification
Name Social Security Number Address: Street: _ New Patient Medical History and Intake Form Medical Marijuana ( MMJ ) Certification Date of Birth Gender: Male Female City: State Zip Code E-mail: Home Phone:
Patient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
Where is your pain located? Please use the diagram below to indicate where most of your pain is located.
Name: Address: Social Security Number: Email Address: Emergency Contact: Primary Care Physician: Name: Address: Phone Number: Date of Birth: Today's date: Cell Phone Number: Phone #: Referring Physician:
MULTI-SYSTEMIC INFECTIOUS DISEASE SYNDROME SYMPTOM QUESTIONNAIRE
MULTI-SYSTEMIC INFECTIOUS DISEASE SYNDROME SYMPTOM QUESTIONNAIRE SECTION 1: SYMPTOM FREQUENCY SCORE Select the frequency of each of the following symptoms. 0 = None 1 = Mild 2 = Moderate 3 = Severe 1.
Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS
WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS Prior to your office visit, we request that you complete this questionnaire. It asks questions not only about your sleeping habits and behavior
Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)
Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical
It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
CISPLATIN INJECTION CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Cisplatin Injection. It does not contain all the available information. It does
The New Mexico Refugee Symptom Checklist-121 (NMRSCL-121)
The New Mexico Refugee Symptom Checklist-121 (NMRSCL-121) Michael Hollifield, MD 2007 New Mexico Refugee Symptom Checklist-121 Instructions: Using the scale beside each symptom, please indicate the degree
Amarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
Please describe, in detail, when the symptoms began:
161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On
Interventional Pain Medicine. P. Tennent Slack, M.D. Dr. Greg Jackson, M.D. Ben Fleming, PA-C
Interventional Pain Medicine P. Tennent Slack, M.D. Dr. Greg Jackson, M.D. Ben Fleming, PA-C Gainesville Braselton Medical Park 1, Suite 300 Medical Plaza B, Suite 402 1315 Jesse Jewell Parkway 1404 River
Diagnose Yourself Problem Description Worksheet. Problem Description Part 1
Problem Description Part 1 1-3. What is the condition for which you need to know the underlying cause? 4. Who are all the people you know for 5. Who else do you know, who you might a fact that are experiencing
Patient Intake Form. Name: Date of Birth: Social Security No.: Address: City: State: Zip:
Patient Intake Form Name: Date of Birth: Social Security No.: Address: City: State: Zip: Phone (circle 1) home / cell / work: Marital Status: Single / Married / Divorced / Widowed Work Status: Employed
Horowitz Lyme-MSlDS Questionnaire
Horowitz Lyme-MSlDS Questionnaire The Horowitz Lyme-MSlDS Questionnaire is not intended to replace the advice of your own physician or other medical professional. You should consult a medical professional
FMS vs CFS substance p elevated in FMS but not is CFS. cellular antiviral enzyme RNaseL is elevated in CFS but not in FMS.
Fibromyalgia widespread pain (right left upper and lower), tender points, cognitive and memory problems, sleep disturbances, unrefreshing sleep, fatigue, morning stiffness, headaches,irritable bowel syndrome,
New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:
New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for
HISTORY OF PRESENT ILLNESS A. TELL US ABOUT YOUR PAIN PROBLEM
1 UT Health Austin Comprehensive Pain Management New Patient Questionnaire Thank you for scheduling a visit with the Comprehensive Pain Management Care Team. The responses you provide to these questions
* CC* PATIENT QUESTIONNAIRE
Pain Center of Michigan *0290341CC* PATIENT QUESTIONNAIRE Patient Name Birthdate Age Home Address City State Zip Home Phone Alternate Phone Referring Physician Primary Care Physician MEDICAL HISTORY Please
A Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016
A Year in Review: Novel Drug Approvals and Important FDA Safety Communications for the Year 2016 Steven F. Nerenberg, Pharm.D. Clinical Assistant Professor Emergency Medicine Pharmacist Rutgers, The State
Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014
- 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases
CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.
Page 1 of 5 CENTRAL CARE POLICY SYMPTOMS OF ILLNESS SUBJECT: SYMPTOMS OF ILLNESS ANNUAL REVIEW MONTH: June RESPONSIBLE FOR REVIEW: Director of Central Care LAST REVISION DATE: June 2009 Policy: Consumers
Inactive Occasional sports Work out 2-3x per week Work out 4-5x per week
3 Washington Circle W, #207/208 Patient ame: Age: Chief Complaint: Please describe what you are being seen for today: What is your hand dominance (which hand do you write with)? Left Right Ambidextrous
The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland
The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland Principle of Harm Reduction First Do No Harm Hippocratic Oath I will use treatment
Hot Topics: Transitions of Care
Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions
ANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care
Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency
Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire
Emory Clinic Department of Neurological Surgery Second Opinion Questionnaire First Name: M.I. Last Name: Date of Birth: Phone: Marital Status: Married Divorced Separated Widowed Single Work Status: Employed
PATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
Arizona Injury Medical Associates, P.L.L.C. Physiatry Care
GENERAL INFORMATION HISTORY QUESTIONNAIRE Name: Today s Date: Age: Date of birth: Sex: M F SS#: Home Address: Cell Phone: Your doctor: Home Phone: Your Attorney (if any): If questions arise after today
City State Zip Code. Ethnic Background: Caucasian African-American Asian Hispanic Native American. Previous. Hobbies/Leisure activities:,,,
History # UPIN # (Please leave blank) Name: First M.I. Last Address: Street (Apt #) City State Zip Code Phone number: ( ) ( ) Home Business Birth Date: / / Day-Month-Year Gender: M F Marital status: (Maiden
Please fill out the following form in as much detail as possible. Please Print. Name. Address. City State Zip. Home Phone Office Phone.
CASE NO. Please fill out the following form in as much detail as possible. Please Print Date Name Address City State Zip Home Phone Office Phone E-mail Address Age Date of Birth Occupation Sex (M) (F)
NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM
Page 1 of 5 Patient Name: Date of Birth: MRN: Encounter #: NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM Thank you for taking
ABOUT YOU (Please print clearly) Name Birth Date Age Sex: Male Female Referring MD Mailing Address: Address
ABOUT YOU (Please print clearly) Name Birth Date Age Sex: Male Female Referring MD Mailing Address: Address Home phone number MD Phone number Work number Any other MD you request we send information to?
PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes.
Name: DOB: PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. TOBACCO USE: Quit Date Cigarettes Packs/Day Number of years smoked Pipe/Cigar Smokeless Tobacco Electronic or E-cigarette Secondhand
Do you think you have Lyme Disease? Fill out The Horowitz MSIDS Questionnaire (HMQ)
Do you think you have Lyme Disease? Fill out The Horowitz MSIDS Questionnaire (HMQ) Answer the following questions as honestly as possible. Think about how you have been feeling over the previous month
The Rehabilitation Institute Cancer Rehabilitation
DO NOT DRILL The Rehabilitation Institute Cancer Rehabilitation Patient Intake Form Your Name: Date: Your date of birth: Age: Who referred you (if a healthcare provider, please provide address)? Doctors
Mass General Thoracic Outlet Syndrome Program Questionnaire
Mass General Thoracic Outlet Syndrome Program Questionnaire Thank you for completing this form. This must be completed and returned by fax to 617-726-7667, by email or by mail to Dr. Donahue s office (address
Antibiotics, Expectorants, and Cough Suppressants. Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital
Antibiotics, Expectorants, and Cough Suppressants Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital Objectives Review the mechanism of action (MOA), dosing, benefits, and various options for:
Eastern Shore MediCann Clinic, LLC
Eastern Shore MediCann Clinic, LLC New Patient Medical History and Intake Form Medical Marijuana Certification Name Date of Birth Social Security Number Gender: Male Female Address: Street: City: State
The Rehabilitation Institute Cancer Rehabilitation
DO NOT DRILL The Rehabilitation Institute Cancer Rehabilitation STAR Patient Intake Form Your Name: Date: Your date of birth: Age: Who referred you (if a healthcare provider, please provide address)? Doctors
New Patient Specialty Intake Form Department of Surgery
This form contains questions specific to the Department of Surgery. If you are new to Baylor College of Medicine and have not been seen in any of our offices, please be sure to complete our New Patient
Past Medical History. Chief Complaint: Appointment Date: Page 1
Appointment Page 1 Chief Complaint: (reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History EYES Yes No Yes Details Glaucoma EAR, NOSE AND THROAT Hearing difficulty
Review of Systems NAME: DATE OF BIRTH: DATE COMPLETED: Dear Patient,
LOS ANGELES CANCER NETWORK NEW PATIENT HEALTH QUESTIONNAIRE NAME: DATE OF BIRTH: DATE COMPLETED: Dear Patient, In order to offer optimal care for you, we need to understand your complete health status
Patient Intake Form for Allegany Ear, Nose, & Throat
Patient Intake Form for Allegany Ear, se, & Throat Patient Name: What brings you to the office today? Who is your primary care doctor? Please list your current medications: Are you allergic to any medications?
BORRELIA AND CO-INFECTION CHECK LIST
Julie A. Griffith, M.D., M.S. Neurology Health Center Pediatric & Neurology 1099 D. St., Suite 208 San Rafael, Ca 94901 Phone (415) 925-1616 Facsimile (415) 259-4011 BORRELIA AND CO-INFECTION CHECK LIST
stoneburner acupuncture
STONEBURNER ACUPUNCTURE, LLC Erin K. Stoneburner, LAc, MAcOM 1135 SE Salmon St, Suite 211 503.784.1660 stoneburner@gmail.com Date: Name: (First) (Middle) (Last) DOB: _ Age: Sex: Address: City/State: ZIP:
Initial Consultation
Today s Date: Initial Consultation Thank you for choosing Apollo Health and Wellness. Please take your time to fill out this form. It will help us to concentrate on areas of your health that need attention
PATIENT INFORMATION SHEET
ALAMO NEUROSURGICAL INSTITUTE 414 W SUNSET, SUITE 205 SAN ANTONIO, TEXAS 78209 WWW.ANI-ONLINE.COM OFF: 210.564.8300 FAX: 210.564.8399 PATIENT INFORMATION SHEET Patient Name (Last, First, Mi): SSN: Street
Monthly Safety Meeting. 25 September 2014 Please sign roster
Monthly Safety Meeting 25 September 2014 Please sign roster Before we begin Please sign the safety meeting roster Used to log safety currency in eservices Safety currency necessary for participation in
HISTORY PAPERWORK FOR APPOINTMENTS WITH DAVID A. PROPST, D.O.
HISTORY PAPERWORK FOR APPOINTMENTS WITH DAVID A. PROPST, D.O. Name: Age: Room Number: Sex: MALE or FEMALE Dominant Hand: RIGHT or LEFT Height Weight Blood pressure HISTORY 1. Did your first symptoms begin
Center for Pain Management New Patient Intake Form
Center for Pain Management New Patient Intake Form Your completed intake paperwork helps our physicians and other providers get to know you and your medical history better. We rely on its accuracy and
Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.
Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient
CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)
IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:
Aspire Pain Medical Center
Aspire Pain Medical Center Welcome to Aspire Pain Medical Center. We are looking forward to providing you with the best care to manage your needs. Please take the time to complete the following questionnaire
T- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less?
Review of STAGE presentation framework (from umass.macy.edu, revised Alicia Monroe, MD from 2005 STFM) S- style organization, sequencing adequate to build a case for your diagnosis or a story T- Timing-
Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015
Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia
New Client Health & Wellness Paper Work
Nutritionally Yours Health Solutions 604 Macy Drive, Roswell GA 30076 678-372-2913 / alanepnd@gmail.com New Client Health & Wellness Paper Work Today's Date Patient Name: _ Parents Name (if patient is
Metabolic Assessment Form
Metabolic Assessment Form Approach Wellness and Aesthetics 200 Forsythe Street Fayetteville, NC 28303 Office: (910) 322-7368 Fax: (910) 483-5796 www.tawellness.net Name: Age: Sex: Date: Part 1: Please
Medical History Form
Medical History Form NAME DOB / / TODAY S DATE MEDICAL HISTORY What medical Conditions do you have? Select all that apply, or write in if not listed: Diabetes High Blood Pressure Thyroid Disorder Heart
Mast Cell Activation Syndrome
Mast Cell Activation Syndrome Clinical Questionnaire Description Today s Date: Patient Name: Please indicate yes or no for the following symptoms and traits: (If you are not familiar with a particular
MEDICAL QUESTIONNAIRE (male)
MEDICAL QUESTIONNAIRE (male) Slievemore Clinic, Old Dublin Road, Stillorgan, Co. Dublin. Tel 01-2000501/502 Fax: 01 2780248 The appointment comprises of a discussion about this questionnaire and a subsequent
NEW SPINE PATIENT. Date Seen: Blood Pressure: Pulse: Weight: Height: O 2. How long (days, weeks, or years) has this complaint/problem been going on?
ROOM #: NEW SPINE PATIENT Date Seen: Blood Pressure: Pulse: Weight: Height: O 2 Sats: For office use only above this line. Patient Name: Referring Physician: Date of Birth: Age: Insurance Carrier: Present
Foreign. Invaders. Fibromyalgia and Diseases of the Immune System. Chapter 9
Foreign Chapter 9 Invaders Fibromyalgia and Diseases of the Immune System In recent years physicians and scientists have become more aware of certain conditions that were once treated as figments of the
SOC SEC #: - - Date of Birth: - - Age: yrs. State: Zip Code: Employer:
PATIENT INFORMATION (PLEASE PRINT) SOC SEC #: - - MRN#: Home Phone: Work Phone: Ext: Address: City: Cell Phone: Date of Birth: - - Age: yrs State: Zip Code: Employer: SEX: Male Female Work Address: City:
Home Address: City: St: Zip: SSN: - - Date of Birth: / / Sex: M F. How did you learn about our clinic?
New Patient Child Intake Pietila Chiropractic, LLC, 12358 River Ridge Blvd., Burnsville, MN 55337 (952) 681-7746 John R. Pietila, DC, DACNB, Jennifer L. Engesether, DC, DACNB, Nicholas C. Moe, DC, Michael
BRAIN STEM CASE HISTORIES CASE HISTORY VII
463 Brain stem Case history BRAIN STEM CASE HISTORIES CASE HISTORY VII A 60 year old man with hypertension wakes one morning with trouble walking. He is feeling dizzy and is sick to his stomach. His wife
IMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
What do you feel are your child s strengths at this time?
PEDIATRIC MEDICAL QUESTIONNAIRE Our ability to draw effective conclusions about your present state of health and how to improve it depends, to a significant extent, on your ability to respond thoughtfully
ABA Chiropractic Holistic Health Center Nutritional Assessment
ABA Chiropractic Holistic Health Center Nutritional Assessment Name: DOB: Age: Social Security # Marital Status: M D S W Employer Occupation: Address: City: Zip: Phone: Alternate phone: Today s date: Emergency
Extended Health Care Company Do you need any help retaining information about your health insurance coverage? Yes No
PATIENT ENTRANCE FORM Date Circle: Male Female Name Birth Date (dd/mm/yy) Age Address Apt # City Province Postal Code Home # Cell # Work # E-MAIL Occupation Employer Name of Emergency Contact Contact #
Emotional Relationships Social Life Sexually Recreation
Name Date Address City State Zip Married Single Partner Divorced Widowed Date of Birth SS# Email Work Phone Home Phone Cell Phone Occupation Referred by Emergency Contact Family Physician Contact May we
Medical History Form
General: Medical History Form 1. Chief Complaint: What are the main health concerns you wish to address? 2. Current and Past Treatment: Have you received treatment for these problems? Yes No, if yes, which:
Safety Assessment in Clinical Trials and Beyond
Safety Assessment in Clinical Trials and Beyond Yuliya Yasinskaya, MD Medical Team Leader Division of Anti-Infective Products Center for Drug Evaluation and Research FDA Clinical Investigator Training
Questionnaire for Lipedema Patients
Questionnaire for Lipedema Patients Name Date of diagnosis Date Name of physician making diagnosis Do you also have lymphedema? What areas of the body are affected? Outside of thighs Inner thighs Knees
HEALTH INFORMATION FORM
#102, 506-71 Ave SW Calgary AB T2V 4V4 Ph 587.352.9199 Fax 1.888.501.1724 info@fullcirclecalgary.ca www.fullcirclecalgary.ca Part 1: BASIC INFORMATION HEALTH INFORMATION FORM Name: Date: Address: City:
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 250 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 500 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE:
Providence Medical Group
Providence Medical Group To our valued patients: In order to provide you with our full attention when you come for an appointment, we would like to ask you to be aware of the following guidelines. Insurance
HEALTH INFORMATION FORM
#102, 506-71 Ave SW Calgary AB T2V 4V4 Ph 587.352.9199 Fax 1.888.501.1724 info@fullcirclecalgary.ca www.fullcirclecalgary.ca Part 1: BASIC INFORMATION HEALTH INFORMATION FORM Name: Date: Address: City:
MEDICAL QUESTIONNAIRE (female)
MEDICAL QUESTIONNAIRE (female) Slievemore Clinic, Old Dublin Road, Stillorgan, Co. Dublin. Tel 01-2000501 The appointment comprises of a discussion about this questionnaire and a subsequent medical examination.
ACUPUNCTURE FOR HEALTH WENDY STALKER R.Ac. Dip.Ac. B.Sc. Name: Date of Birth: Date:
Name: Date of Birth: Date: Address: Postal Code: Occupation: Telephone: Day: Cell Phone: E-mail address: Emergency Contact: Evening: Telephone: Male Female Where did you hear about Acupuncture for Health?
PLEASE DESCRIBE YOUR PRIMARY HEALTH CONCERNS
Dr. Kenzie Maloy, DC, DABCI, DACCP, DACBN 505 E. Main St. Suite B Hermiston, OR 97838 Phone:541-371-3700 Fax:541-515-7022 PERSONAL INFORMATION: First Name: Last Name: Middle Initial: Email for doctor communications:
McLaren Cardiothoracic and Vascular PATIENT HISTORY FORM
McLaren Cardiothoracic and Vascular PATIENT HISTORY FORM Please complete this form and bring it with you to your appointment Appointment Date Appointment Time Name Referring Physician Date of Birth Please
NEW PATIENT INFORMATION FORM
NEW PATIENT INFORMATION FORM Name: LAST FIRST MIDDLE Date of Birth: Sex: Marital Status: SS Number: Address: City: State: Zip Phone: Home Cell Work Email: Communication Preference: Patient Portal Phone